LONDON, UK – Existing adoption rates and commercial success of launched Monoclonal Antibodies (mAbs) for therapeutics have established a strong platform for these products. Broadening the horizontal indications for existing mAbs, expanding the applications of mAbs in new therapeutic areas and developing innovative and faster drug delivery mechanism are the current trends in the mAbs market.
Monoclonal Antibodies (mAbs) are mono-specific high molecular weight complex proteins which are capable of post translational modifications like glycosylation.
They are predominantly used in the treatment of cancer and autoimmune and inflammatory disorders. Other areas include cardiovascular and infectious diseases and organ transplants.
Over 45 mAbs are currently used. Drugs developed for cancer and Rheumatoid Arthritis (RA) account for 75% of the total market.
The European therapeutic monoclonal antibodies market, accounting for approximately 33.1% of the global market, is estimated at $19.01 billion in 2011 and is expected to reach $42.37 billion in 2018 with a CAGR of 12.1%.
“Robust activities and strong product potential across both existing and pipeline products drive M&A activities across the monoclonal antibodies market,” explains Deepika Pramod Chopda, Research Associate at Frost & Sullivan. “The alliances commonly observed include that of Big Pharma acquiring small biotech companies helping growth and development across the biologics industry.”
While a strong product pipeline, premium pricing trends and growing market opportunities and success from existing product line-up drive the mAbs market, high developmental costs, the financing of mAbs therapeutics in public healthcare, alternative treatment options within biologics and competition from biosimilars are all factors impeding the market growth.
Therapeutic Monoclonal Antibibodies market for their innovative and lucrative offerings into the biopharmaceuticals market resulted in a positive revenue growth rate through the economic recession. “Growing demand for improvised therapy allure mAbs against conventional chemical drugs for therapeutics,” concludes Ms Chopda. “Strong pipeline and broadening product segments to ophthalmology, respiratory infections will promote their development.”
Frost & Sullivan recently organised an on-demand analyst briefing entitled “Is Biologics the Answer to Rising Disease Incidence.” The web-conference summarizes Ms Chopda’s findings, identifying the market’s drivers and constraints and looking at the pipeline and R&D developments made within the Monoclonal Antibodies market.
This web-conference will benefit investors from the Big Pharma segment to evaluate the development made by small biotech companies promoting Mergers & Acquisitions and Product/Technology Alliance opportunities. Healthcare/medical professionals, venture capitalists and drug manufacturers looking to widen the knowledge about mAbs are also a suitable audience.